Next Phase Newsletter

A newly established angel investor group headquartered in the US with ties/members in China is looking for innovative opportunities in the healthcare sector. The firm invest in early stages, including seed and series A, The firm’s typical check size ranges from $100K – $500K. The firm is open to USA based companies. 
 
The firm is primarily focused on investing in digital health and medical devices. The firm is indication- and modality- agnostic. 
 
The firm is open to both co-investing and leading, though prefers to co-invest. The firm likes with see a management team from a relevant domain with previous business experience. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A healthcare investment arm of a multi-strategy asset management firm focuses on early-stage opportunities in the medical device and digital health sectors, having invested approximately $250M USD in healthcare and medtech. The firm typically engages in Series A rounds and beyond, with check sizes ranging from $5M to $20M USD, and follow-on investments are a possibility. While the firm primarily focuses on the US (especially the Bay Area) and Europe, it remains open to global opportunities. 
 
The firm primarily considers opportunities in medical devices and digital health. Traditional asset-driven therapeutics are out of scope. The firm is agnostic to subsectors and indications but prefers disease areas with large addressable markets and companies with a clear reimbursement strategy. Some areas of interest include cardiovascular, ophthalmology, and diabetes. The fund typically evaluates clinical-stage opportunities but is open to considering design-stage companies, provided they have strong validation. 
 
The firm does not have specific requirements for a company’s founding team. However, the firm prefers founders with experience or a successful track record. 
 
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An investment firm manages funds for a major health insurance company in the US. The firm seeks to invest in healthcare companies of strategic interest to this insurance company while seeking strong financial returns. With the fund, the firm is looking to make investments ranging from $1 – $20 million over the lifetime of the investment in stages ranging anywhere from seed to buyout. The firm is actively reviewing new opportunities and will consider companies located around the globe that are commercializing in the US or plan to in the near future. The firm also manages other funds that seek to invest in insurtech companies. The firm partners with payers and providers to drive innovation in healthcare, with a focus in medical devices, diagnostics, and AI solutions for providers. 
 
Within the healthcare space, the firm looks to invest across Healthcare IT, Services, Diagnostics, and Devices. 
 
The firm is looking for companies with experienced management teams and prefers working with complete teams although they also have experience and are willing to work with incomplete management teams as well. The firm is looking for privately held companies and prefers to lead in rounds but can co-invest in certain circumstances. The firm generally looks to take a board seat following an investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An early stage VC fund based in the US currently has $250M under management. The group focuses on highly technical, very early stage companies. The typical investment size is between $1M to $2M and they’re open to lead, co-lead and follow. The group also syndicates with other investors for larger investments. The firm looks to make investments across the globe. 

The firm have been highly active in deep tech/ R&D intensive investments, and have a significant biotech portfolio of notable/renowned companies in the industry. 
 
Currently, the firm’s team is focusing on Neuroscience and brain tech, like Neuromodulation, BCI, precision neuroscience, and infra from data driven angles, like AI in drug development, Multi Omics, from Seed to Series A. 
 
The firm focuses on investments in private companies and typically invests in pre-clinical and early clinical stage companies with strong and experienced management teams. The firm will take a board seat or observer seat occasionally, depending on the investments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An early-stage venture capital firm headquartered in the US invests in life science and healthcare companies at Seed and potentially Series A stages. The firm also has the ability to incubate companies. The firm can act as a lead investor for the Seed round and can co-lead or follow for Series A. Typical check sizes range between USD $50k-500k. The firm is open to global companies but has a strong focus on the U.S. and Europe. 
 
The firm is mainly interested in therapeutics and is agnostic with modalities. The firm is opportunistic in terms of medical devices and life science tools. The firm is indication-agnostic. Companies of interest are typically in in-development or clinical trial stages. 
 
As the firm like to be hands on and are active investors, they prefer to take a board or observer seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A hybrid family office and operating company based can make investments ranging from $500k-100M into companies, and due to its funding structure, has no requirements for holding period or capital structure. The firm makes investments in the forms of equity, controlling interest, in-licensing, MBO/LBO, growth capital and is also willing to co-invest. The firm is looking for companies located around the globe and makes opportunistic and strategic investments, and does not have a target minimum or maximum number of investments for any given year. 
 
The firm is primarily looking for companies in the Therapeutics sector and is willing to consider all indications including orphan diseases, though they have some additional interest/experience is areas of ophthalmology, dermatology, diabetes, oncology, and Personalized Medicine including Proteomics and Genomics. The firm is most interested in companies that are clinical stage, but also capable of supporting companies nearing commercialization where the firm is capable of utilizing its operating company to scale up the company’s sales, marketing and distribution. That being said the firm has made earlier stage investments in the past and is open to considering highly innovative and compelling early stage companies. 
 
The firm looks to work with management teams with experience and grit and generally looks to take a board seat although it is not a requirement. The firm looks to leverage the use of its operating company to assist the company’s sales marketing and distribution efforts as well as providing assistance in operations management and product development.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm actively works to facilitate the creation, improvement, and validation of new medicines and health technologies. Its partnerships with portfolio companies and industry open up new horizons in precision medicine in realizing its mission to accelerate the innovation cycle through accessible solutions designed to improve patient’s health. Typically participating in Series A rounds, initial check size ranges between $1M-5M USD. The firm can act as a lead or co-investor and is open to global companies. 
 
The firm’s investments will transform healthcare through close collaborations with its metabolomics laboratory, merging AI and biomarker analysis to support the international growth of innovative companies. The firm is interested in life sciences facilitating drug discovery, and improving diagnosis, treatment, and monitoring of metabolomic conditions such as cancer, cardiovascular diseases, diabetes, antimicrobial, antibiotics resistance, and neurodegenerative diseases. 
 
The firm prefers to take a board or observer seat. Investments will be complemented with lab services to measure toxicity and response or therapies or accuracy of health technology. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.